Pliant Therapeutics has attracted $100m in a series C round led by Novartis, four years after it was founded to commercialise UC San Francisco research into fibrosis treatment.
Pharmaceutical firm Novartis led a $100m series C round for US-based fibrosis therapy developer Pliant Therapeutics yesterday that increased its total funding to $207m.
Redmile, Farallon Capital Management, Cormorant Asset Management, Surveyor Capital, Logos Capital, Eventide Asset Management, Cowen Healthcare Investments, Schroder Adveq, Menlo Ventures, SCubed Capital, Agent Capital and unnamed additional backers filled out the round.
Pliant is working on treatments that can either slow or halt the progression of life-threatening fibrotic diseases. Its lead asset, PLN-74809, is aimed…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
